LongeVC Portfolio Company Unnatural Products Announces Licensing Agreement with Novartis, worth up to $100M upfront and pre-IND, up to $1.7B
LongeVC portfolio company Unnatural Products (UNP) has signed a research collaboration and licensing agreement with Novartis to develop macrocyclic peptide therapeutics targeting cardiovascular disease.
UNP's platform combines AI-guided drug design with rapid synthesis to create a class of molecules that blend the precision of biologics with the versatility of small molecules — enabling treatment of targets that have historically been too difficult to drug. Novartis will take the lead on clinical development, manufacturing, and global commercialization.
The terms of the agreement reflect the scale of the opportunity: UNP will receive up to $100 million in upfront and pre-IND milestone payments, up to $1.7 billion in development, regulatory, and commercial milestones, and tiered royalties on net sales.